Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

pany expects a decrease in gross margin as a percent of total revenue compared to the fourth quarter of 2008.

Marketing, selling, and administrative expenses are projected to show flat to low-single digit growth. Research and development expenses are projected to grow in the high-single digits on a pro forma non-GAAP basis and in the low-double digits on a reported basis.

Other income is expected to be a net loss of between $200 million and $250 million. The effective tax rate is expected to be approximately 21 percent on a pro forma non-GAAP basis and approximately 20 percent on a reported basis. Capital expenditures are expected to be less than $1.0 billion. The company expects continued strong operating cash flow.

2010 Financial Guidance

The company provided financial guidance for 2010, excluding the potential impact of health care reform in the U.S. In 2010, the company expects earnings per share of $4.65 to $4.85 on both a reported and pro forma non-GAAP basis.

2010 Earnings Per Share Expectations:


                                 2010             2009
                             Expectations     Expectations   % Growth
                             ------------     ------------   --------
Earnings per share
 (reported)                 $4.65 to $4.85   $3.90 to $4.00  16% to 24%
Charges related to Zyprexa
 litigation                       -                .13
Asset impairments and
 restructuring charges
 (included in asset
 impairments, restructuring
 and other special charges)       -                .26
                            --------------   --------------
Earnings per share (pro
 forma non-GAAP)            $4.65 to $4.85    4.30 to $4.40   6% to 13%
                            --------------   --------------

The company expects volume-driven revenue growth in the high-single digits, driven primarily by Alimta, Cymbalta, Humalog, Cialis, Effient and the exenati
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... RALEIGH, N.C. , May 22, 2013 ... pleased to announce the launch of their web site ... reports [STEPh Reports].  About STEPh Reports ... drugs in development.  Each STEPh Report ... clinical trials data, projected launch year, company, and specific ...
(Date:5/22/2013)... N.J. , May 22, 2013 MEDIFIRST ... opportunity to update shareholders about some recent company developments. ... expand its avenues of communication with shareholders. Integrating social ... launched a Facebook page and will post updates on ... Twitter hashtag is #medifirstusa. Says CEO ...
(Date:5/22/2013)... , May 22, 2013 Ranbaxy ... Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on ... in recent years to address past conduct under ... Daiichi Sankyo continues to support ... the conduct of the past which led to ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
... dermatitis, the common, chronic, inflammatory skin disease marked by ... the past two decades and affects a disproportionate number ... to 20 percent of children in the United States ... dermatitis in the first few years of life. By ...
... Cash Position--Biologics License Application for Wrinkles/Nasolabial Folds Indication ... EXTON, Pa., March 5 Isolagen(TM), Inc. (Amex: ... efficacy results from a Phase II/III clinical study ... treatment of moderate to severe acne scars. The ...
Cached Medicine Technology:Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 2Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 3Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 4Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 5Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant 6
(Date:5/22/2013)... study suggests that disturbed sleep in adolescents is ... uncertainly about future success. However, perceived support ... have a protective effect. , Results show ... mood and greater uncertainty about future success. Higher ... teachers were associated with significantly fewer sleep disruptions ...
(Date:5/22/2013)... the parents are married are less likely to be ... the University of Houston. , "Childhood obesity is a ... one-third of all U.S. children ages 2-17 overweight or ... sociology at Rice and director of Rice,s Kinder Institute ... been conducted to explore the impact of family structure ...
(Date:5/22/2013)... May 22, 2013 Slip and fall ... by a number of factors. A December 2010 CDC ... following hazards as the most common: contaminants on the ... weather conditions, inadequate lighting, and lack of handrails (i). ... bruises, strained ligaments and muscles, fractures, broken bones, ...
(Date:5/22/2013)... Monroe, OH (PRWEB) May 22, 2013 ... indoor air quality merchandise ranging from furnace filters, ... DiscountFurnaceFilters.com is excited to add Stadler Form's ... a fashionable summer product line (fans, aroma diffusers ... , Stadler Form’s Otto Fan is the perfect ...
(Date:5/22/2013)... Peak Solar introduces unique, interactive solar training seminars, ... customers make informed buying choices. Research studies tell companies ... is to give them the tools needed to make ... heart. Solar training seminars will be introduced onto the ... solar kits . , Poised to help both residential ...
Breaking Medicine News(10 mins):Health News:Parent and teacher support protects teens from sleep problems and depression 2Health News:Children of married parents less likely to be obese 2Health News:Children of married parents less likely to be obese 3Health News:Law Firm Releases Slip and Fall Accident Informational Graphic to Show the Frequency and Cost of These Incidents 2Health News:Law Firm Releases Slip and Fall Accident Informational Graphic to Show the Frequency and Cost of These Incidents 3Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2Health News:Online Solar Training Seminars Aimed at Informing Consumers 2
... consumer focused new and improved interface. The most highlighting feature of ... cyber consumers to choose and buy their niche medicines any time. ... ... USA,s most reliable online pharmacy, launched a brand new customer focused, ...
... Multiple customer agreements for Soarian Clinicals and Siemens ... for the system that streamlines the flow of ... 5 Siemens ( ... customer contracts and installations, along with strong existing-customer ...
... allergies, so be prepared, expert says , , SUNDAY, April ... child is one of the more than 35 million Americans ... the youngster enjoy being outside, one expert says. , ... with MCG Pediatric Primary Care Associates and MCGHealth Children,s Medical ...
... of a Post-Merger Integration and Restructuring Practice. The new practice ... posed by increasing financial pressures and the consolidating health care market. ... ... Health Strategies & Solutions, Inc. (HS&S), the nation,s leading health ...
... man that suffers from depression, erectile dysfunction, fatigue, poor concentration or hot ... is advising men ages 35 and over to have their hormone levels ... 4 out of 5 men age 40 have low testosterone, the leading ... ...
... Mass., April 4 Inverness Medical Innovations, Inc. (NYSE: ... individuals to take charge of their health at home ... announced today that it will attend the upcoming Goldman ... Wednesday, April 8, 2009 at the Goldman Sachs Conference ...
Cached Medicine News:Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 2Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 3Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 2Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 3Health News:Siemens Announces Latest Contracts, Recent 'Go Lives,' and Strong Customer Support for its Workflow-Enhancing Healthcare IT Solution Soarian Clinicals, at HIMSS 2009 4Health News:Breathe Easier Knowing Spring's Pollen Triggers 2Health News:The Nation's Leading Health Care Strategy Firm Launches Post-Merger Integration Practice 2Health News:The Nation's Leading Health Care Strategy Firm Launches Post-Merger Integration Practice 3Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 2Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 3Health News:Male Hormone Treatment Provider Announces Family Doctor Alert 4
... complete line of flowmeters, available in ... . They are all available in ... suit your application. With color coded ... gas in use, the Amvex Flowmeter ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... line of flowmeters, available in oxygen, ... They are all available in a ... your application. With color coded labels ... in use, the Amvex Flowmeter is ...
... line of flowmeters, available in oxygen, air, heliox and ... variety of calibrations to best suit your application. With ... in use, the Amvex Flowmeter is a user friendly ... I. For Power Take-Off add PT to the end ...
Medicine Products: